Evidence of an increasingly common problem
A 2.7-fold increase in incidence
According to Surveillance, Epidemiology, and End Results (SEER) data, the age-adjusted incidence of NET rose from 1.9 to 5.25 cases per 100,000 people between 1973 and 2004.4 These are the most current SEER data available encompassing all NET types and anatomic locations.
The diagnosed incidence of NET is predicted to continue rising at a faster rate than other malignant neoplasms.7 This may be due to improved surveillance and diagnostic techniques, and may also be attributed, in part, to the increased use of gastrointestinal (GI) imaging modalities, such as gastroscopy, colonoscopy, and capsule endoscopy, in routine clinical practice.8,9
Have you seen NET in your practice?
SEER data (1973-2004) also demonstrate that the prevalence of NET is similar to that of other types of GI cancers.4
Most NET occur sporadically. However, some may be associated with genetic syndromes, notably multiple endocrine neoplasia type 1 (MEN-1), as well as MEN-2a and MEN-2b.2,3
Early NET detection may help reduce rates of metastatic disease
As with other solid tumors, 5-year survival rates for patients with NET depend largely on the tumor histology and extent of disease. The table at right shows 5-year and median survival for both well-differentiated NET and poorly differentiated neuroendocrine neoplasms, according to long-term SEER data (1973-2004).4
About 50% of patients with reported disease stage have either regional or distant metastases at diagnosis.4
This reflects, in part, the long delay that can occur (up to 5 to 7 years for certain types of NET)2 before patients are definitively diagnosed and optimally managed.